奥马珠单抗治疗重度非变应性哮喘患者的长期获益。
Long-term benefits of omalizumab in a patient with severe non-allergic asthma.
机构信息
Department of Respiratory Diseases, Santa Maria Nuova Hospital, Reggio, Emilia, Italy.
出版信息
Allergy Asthma Clin Immunol. 2011 May 24;7(1):9. doi: 10.1186/1710-1492-7-9.
Abstract
INTRODUCTION
Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.
CASE PRESENTATION
We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.
CONCLUSION
Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.
摘要
简介
目前，奥马珠单抗适用于治疗尽管接受了最佳治疗但仍存在严重过敏且无法控制的哮喘患者。
病例介绍
我们研究了一名 52 岁男性患者，他患有严重的非变应性类固醇耐药性哮喘，总 IgE 水平升高且存在许多合并症。经过 3 年奥马珠单抗治疗，他在住院、恶化、生活质量和肺功能方面的疾病控制得到了显著改善，安全性良好。
结论
我们的病例表明，经过长期随访，奥马珠单抗如何在非变应性严重哮喘中有效。因此，希望进一步的研究能够确定指标，以便为临床医生提供有关可对单克隆抗 IgE 抗体有反应的患者的信息，即使是非变应性患者。
相似文献
1
Long-term benefits of omalizumab in a patient with severe non-allergic asthma.奥马珠单抗治疗重度非变应性哮喘患者的长期获益。
Allergy Asthma Clin Immunol. 2011 May 24;7(1):9. doi: 10.1186/1710-1492-7-9.
2
Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.奥马珠单抗治疗一名患有重度持续性哮喘并伴有嗜酸性食管炎的13岁男孩。
Ital J Pediatr. 2016 Mar 22;42:32. doi: 10.1186/s13052-016-0243-x.
3
Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.重度过敏性哮喘患者长期奥马珠单抗治疗的评估——重度哮喘的长期奥马珠单抗治疗
J Asthma. 2013 Aug;50(6):687-94. doi: 10.3109/02770903.2013.792348. Epub 2013 May 9.
4
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.重组人源化抗IgE单克隆抗体（奥马珠单抗）治疗中重度过敏性哮喘
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. doi: 10.2174/187221307782418900.
5
Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.奥马珠单抗治疗伴过敏性哮喘和特应性皮炎患者的生活质量改善：一年随访。
Eur J Med Res. 2011 Sep 12;16(9):407-10. doi: 10.1186/2047-783x-16-9-407.
6
The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.奥马珠单抗对患者和医生报告的哮喘控制的长期有效性和安全性：一项为期三年的真实世界观察性研究。
Adv Ther. 2020 Jan;37(1):353-363. doi: 10.1007/s12325-019-01135-w. Epub 2019 Nov 18.
7
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.抗IgE单克隆抗体（奥马珠单抗）在治疗特应性哮喘和过敏性呼吸道疾病中的应用
Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. doi: 10.2174/1568010043343615.
8
Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.奥马珠单抗：抗IgE单克隆抗体E25、E25、人源化抗IgE单克隆抗体、IGE 025、单克隆抗体E25、奥立珠单抗、Xolair、重组人源化抗IgE单克隆抗体E25
BioDrugs. 2002;16(5):380-6. doi: 10.2165/00063030-200216050-00009.
9
Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).用重组人源化抗IgE单克隆抗体（奥马珠单抗）治疗中重度过敏性哮喘。
Treat Respir Med. 2006;5(6):393-8. doi: 10.2165/00151829-200605060-00004.
10
Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.奥马珠单抗治疗哮喘的药代动力学、药效学及临床疗效
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1503-1511. doi: 10.1080/17425255.2016.1248403. Epub 2016 Oct 27.
引用本文的文献
1
Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.重度哮喘的靶向生物疗法：作用机制、生物标志物及临床应用
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1021. doi: 10.3390/ph18071021.
2
Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE.奥马珠单抗治疗低IgE哮喘患者的疗效
Case Rep Pulmonol. 2020 Sep 14;2020:8898454. doi: 10.1155/2020/8898454. eCollection 2020.
3
Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights.重度嗜酸性粒细胞性哮喘的抗白细胞介素-5疗法：文献综述与实践见解
J Asthma Allergy. 2020 Sep 9;13:301-313. doi: 10.2147/JAA.S258594. eCollection 2020.
4
Severe refractory asthma: current treatment options and ongoing research.重度难治性哮喘：当前的治疗选择与正在进行的研究
Drugs Context. 2018 Dec 5;7:212561. doi: 10.7573/dic.212561. eCollection 2018.
5
Omalizumab for Severe Asthma: Beyond Allergic Asthma.奥马珠单抗治疗重症哮喘：超越过敏性哮喘。
Biomed Res Int. 2018 Sep 17;2018:3254094. doi: 10.1155/2018/3254094. eCollection 2018.
6
Role of IL-15 in the modulation of TGF-β1-mediated inflammation in asthma.白细胞介素-15在哮喘中调节转化生长因子-β1介导的炎症中的作用。
Exp Ther Med. 2017 Nov;14(5):4533-4540. doi: 10.3892/etm.2017.5108. Epub 2017 Sep 5.
7
Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?重度难治性哮喘的创新治疗方法：如何为合适的患者选择正确的治疗方案？
J Asthma Allergy. 2017 Aug 30;10:237-247. doi: 10.2147/JAA.S144100. eCollection 2017.
8
Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.阿司匹林加重性呼吸系统疾病：患病率、诊断、治疗及未来考量
Am J Rhinol Allergy. 2016 Nov 1;30(6):407-413. doi: 10.2500/ajra.2016.30.4370.
9
Personalized Medicine in Allergy.过敏领域的个性化医疗
Allergy Asthma Immunol Res. 2017 Jan;9(1):15-24. doi: 10.4168/aair.2017.9.1.15.
10
Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies.老年哮喘管理中的药物治疗：临床研究综述
Asia Pac Allergy. 2016 Jan;6(1):3-15. doi: 10.5415/apallergy.2016.6.1.3. Epub 2016 Jan 27.
本文引用的文献
1
Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.抗 IgE 抗体（奥马珠单抗）治疗对重度哮喘和阴性皮肤点刺试验结果患者的有益作用。
Chest. 2011 Jan;139(1):190-3. doi: 10.1378/chest.10-0128.
2
Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.皮下奥马珠单抗对比安慰剂作为附加疗法用于儿童和成人哮喘患者的皮质类固醇治疗：一项系统评价。
Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5.
3
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.奥马珠单抗治疗重度持续性过敏性哮喘患者的“真实世界”疗效：PERSIST 研究。
Respir Med. 2009 Nov;103(11):1633-42. doi: 10.1016/j.rmed.2009.06.014. Epub 2009 Jul 19.
4
Omalizumab decreases nonspecific airway hyperresponsiveness in vitro.奥马珠单抗在体外可降低非特异性气道高反应性。
Allergy. 2007 Feb;62(2):154-61. doi: 10.1111/j.1398-9995.2006.01243.x.
5
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.一种基于机制的奥马珠单抗群体药代动力学和药效学结合模型。
Br J Clin Pharmacol. 2007 May;63(5):548-61. doi: 10.1111/j.1365-2125.2006.02803.x. Epub 2006 Nov 10.
6
Anti-IgE for chronic asthma in adults and children.用于成人和儿童慢性哮喘的抗IgE药物。
Cochrane Database Syst Rev. 2006 Apr 19(2):CD003559. doi: 10.1002/14651858.CD003559.pub3.
7
Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.用于定量接受奥马珠单抗（Xolair）治疗的过敏患者血清中游离和总IgE水平的免疫学方法。
J Immunol Methods. 2005 Aug;303(1-2):81-91. doi: 10.1016/j.jim.2005.06.008.
8
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.奥马珠单抗在过敏性疾病中的抗免疫球蛋白E治疗：抗炎活性和临床疗效的最新进展
Clin Exp Allergy. 2005 Apr;35(4):408-16. doi: 10.1111/j.1365-2222.2005.02191.x.
9
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.对于重度持续性哮喘患者，尽管接受了最佳可用治疗（《全球哮喘防治创议》2002版第4步治疗）但控制不佳时，奥马珠单抗作为附加治疗的益处：INNOVATE研究。
Allergy. 2005 Mar;60(3):309-16. doi: 10.1111/j.1398-9995.2004.00772.x.
10
Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals.血清总免疫球蛋白E升高与非过敏性个体的哮喘有关。
Eur Respir J. 2000 Oct;16(4):609-14. doi: 10.1034/j.1399-3003.2000.16d07.x.
Zotero 插件